The First Protein Degrader Drug ARV-110’s Latest Clinical Data: Preliminary Display of Anti-tumor Activity

Among the drugs developed in Arvinas, ARV-110 is the first oral PRAOTC small molecule drug to enter clinical trials in the field of proteolytic targeted chimerism, selectively targeting the degradation of androgenRead More…